RecruitingPhase 1NCT05836324

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Sponsor

Incyte Corporation

Enrollment

570 participants

Start Date

Jul 24, 2023

Study Type

INTERVENTIONAL

Conditions

Solid Tumors Advanced Solid Tumors Metastatic Solid Tumors

Summary

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cetuximab, a drug called FOLFIRI, and others for people with advanced solid tumors, metastatic solid tumors, and other related conditions. The study is currently recruiting participants at 36 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCA33890

INCA33890 will be administered at protocol defined dose.

DRUGbevacizumab

Bevacizumab will be administered at protocol defined dose.

DRUGFOLFIRI

FOLFIRI will be administered at protocol defined dose.

DRUGFOLFOX

FOLFOX will be administered at protocol defined dose.

DRUGCetuximab

Cetuximab will be administered at protocol defined dose.

DRUGADG126

ADG126 will be administered at protocol defined dose.

Locations(39)

The Angeles Clinic and Research Institute

Los Angeles, California, United States

Valkyrie Clinical Trials

Los Angeles, California, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Cancer and Hematology Centers of Western Michigan-Start Midwest

Grand Rapids, Michigan, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

Nyu Langone Health - Long Island Hospital

Mineola, New York, United States

Laura and Isaac Perlmutter Cancer Center

New York, New York, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Lifespan Cancer Research Institute

Providence, Rhode Island, United States

University of Texas Md Anderson Cancer Center

Houston, Texas, United States

South Texas Accelerated Research Therapeutics

San Antonio, Texas, United States

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China

Peking University People'S Hospital

Beijing, China

The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu)

Hangzhou, China

Rigshospitalet Uni of Hospital of Copenhagen

Copenhagen, Denmark

Herlev Og Gentofte Hospital

Herlev, Denmark

Odense University Hospital

Odense C, Denmark

Vejle Hospital

Vejle, Denmark

Centre Leon Berard

Lyon, France

Institut Gustave Roussy

Villejuif, France

Fondazione Irccs Istituto Nazionale Dei Tumori

Milan, Italy

Irccs Istituto Clinico Humanitas

Rozzano, Italy

Centro Ricerche Cliniche Di Verona

Verona, Italy

Kansai Medical University Hospital

Hirakata, Japan

National Cancer Center Hospital

Tokyo, Japan

The Cancer Institute Hospital of Jfcr

Tokyo, Japan

Start Barcelona

Barcelona, Spain

Hospital General Universitario Vall D Hebron

Barcelona, Spain

Fundacion Jimenez Diaz University Hospital

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Centro Integral Oncologico Clara Campal

Madrid, Spain

Istituto Oncologico Della Svizzera Italiana

Bellinzona, Switzerland

Centre Hospitalier Universitaire Vaudois (Chuv)

Lausanne, Switzerland

Kantonsspital St. Gallen

Sankt Gallen, Switzerland

Cambridge University Hospitals Nhs Foundation Trust

Cambridge, United Kingdom

Guys and St Thomas Nhs Foundation Trust

London, United Kingdom

Imperial College Healthcare Nhs Trust - Hammersmith Hospital

London, United Kingdom

The Christie Nhs Foundation Trust Uk

Manchester, United Kingdom

Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust

Newcastle upon Tyne, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05836324

Related Trials

A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

NCT072312111 location

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT045704235 locations

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

NCT064455174 locations

Personalized Neoantigen Peptide Vaccines for Solid Tumors

NCT070022031 location